Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases.

Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID-19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID-19 vaccination were enrolled in our case-series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty-five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18-91) were enrolled in our study. Twenty-two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new-onset lichen planus (LP) and 1 (4%) patient manifested LP flare-up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new-onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare-up. Other new-onset cases were as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID-19 vaccines.

Pityriasis Lichenoides Chronica in a Patient With Ankylosing Spondylitis Treated With Etanercept.

Pityriasis lichenoides is a scarce cutaneous disorder with unknown etiology. It contains a range of clinical manifestations including acute papular lesions that quickly grow into pseudo vesicles and central necrosis to small, scaling, benign-appearing papules.1,2.

Pityriasis Lichenoides Chronica in a Patient With Ankylosing Spondylitis Treated With Etanercept.

BACKGROUND: Pityriasis lichenoides chronica, a papulosquamous disorder often considered a subtype of pityriasis lichenoides. It is considered a clonal T-cell disorder, which may be associated with cutaneous T-cell lymphoma that may develops in response to foreign antigens. CASE PRESENTATION: We present a 38-year-old male patient with ankylosing spondylitis who was on treatment with etanercept. After 8 weeks of treatment, the patient presented with scaly erythematous papules, on the back and arms. He was diagnosed clinically with pityriasis lichenoides chronica. CONCLUSION: Pityriasis lichenoides chronica should be included among the broad clinical spectrum of chronic inflammatory skin diseases which may occur during treatment with TNF-alpha antagonists. J Drugs Dermatol. 2020;19(5): doi:10.36849/JDD.2020.2191.

Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine.

The aetiology of pityriasis lichenoides (PL) is unknown. One major pathogenic theory suggests that PL is a lymphoproliferative disease or inflammatory reaction triggered by an antigenic stimulus, such as a virus or other infectious agent. We report the second case of PL et varioliformis acuta (PLEVA) occurring after measles vaccination and the first following the combined measles, mumps, rubella vaccination.

Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors / Pitiriasis liquenoide crónica asociada con el uso de inhibidores de la reductasa de HMG-CoA

Herein, we present three cases of Pityriasis lichenoides chronica (PLC) in patients who developed the rash after use of 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase inhibitors. The patients had complete resolution after standard treatment by dermatologists and withdrawal of the offending agents. In one case, the patient had a previous episode of a similar rash that occurred with HMG-CoA reductase inhibitors use many years previously. Pityriasis lichenoides chronica is a condition of unknown aetiology. Several agents have been associated with its presentation. We postulate HMG-CoA reductase inhibition in skin presents a final common pathway for the presentation of PLC in select patients.

Se presentan tres casos de pitiriasis liquenoide crónica (PLC) en pacientes que desarrollaron una erupción tras el uso de inhibidores de la reductasa de la hidroxi-metilglutaril-coenzima A (HMG-CoA). Los pacientes tuvieron resolución completa después del tratamiento estándar dado por los dermatólogos, y la suspensión de los agentes ofensivos. En un caso, el paciente tuvo un episodio de una erupción similar anterior, que ocurrió debido al uso de inhibidores de la reductasa de HMG-CoA muchos años atrás. La pitiriasis liquenoide crónica es una condición de etiología desconocida. Varios agentes han sido asociados con su manifestación. Se postula que la inhibición de la reductasa de HMG-CoA presenta un camino final común para la manifestación de PLC en determinados pacientes.

Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.

Herein, we present three cases of Pityriasis lichenoides chronica (PLC) in patients who developed the rash after use of 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMG-CoA) reductase inhibitors. The patients had complete resolution after standard treatment by dermatologists and withdrawal of the offending agents. In one case, the patient had a previous episode of a similar rash that occurred with HMG-CoA reductase inhibitors use many years previously. Pityriasis lichenoides chronica is a condition of unknown aetiology. Several agents have been associated with its presentation. We postulate HMG-CoA reductase inhibition in skin presents a final common pathway for the presentation of PLC in select patients.

Triggering of pityriasis lichenoides et varioliformis acuta by radiocontrast iodide.

OBJECTIVE: Pityriasis lichenoides et varioliformis acuta (PLEVA) is characterized by 2-3 mm erythematous papules that became vesiculopustular with hemorrhagic necrosis. METHOD & MATERIAL: A 45-year-old lady, a known case of parathyroid adenoma, presented with a generalized itchy skin rash starting four days after radiocontrast iodide injection. RESULT: There are some reports of provocation of PLEVA by tegafur and astemizole. CONCLUSION: We report for the first time the triggering of PLEVA by radiocontrast iodide injection.

Mucha-Habermann disease-like eruptions due to Tegafur.

The first case of Mucha-Habermann disease-like drug eruptions due to Tegafur is reported. A 59-year-old man noticed various skin lesions after he had taken 300 mg of Tegafur daily for about 200 days. The patient had papulonecrotic eruptions on his trunk and extremities. The histology from a papular lesion revealed epidermal necrosis surrounded by spongiosis, perivascular inflammatory infiltrations composed of lymphocytes and erythrocytes, and endothelial swelling. The etiology of Mucha-Habermann disease is not known, but an immune mechanism may be supported by our case.

[Pityriasis-lichenoides-et-varioliformis-acuta-like drug exanthema caused by astemizole]. / Pityriasis-lichenoides-et-varioliformis-acutaähnliches Arzneiexanthem durch Astemizol.

We report on a 40-year-old male patient who developed an unusual generalized drug eruption taking the form of a histologically confirmed pityriasis lichenoides et varioliformis acuta (PLEVA) after oral intake of the H1-antagonist astemizole. On two occasions, independently repeated medication with astemizole exacerbated the typical rash again. Oral exposure and the specific lymphocyte transformation test confirmed the suspected causal connection between astemizole and PLEVA.